TABLE 1

Baseline demographics and clinical characteristics (full analysis set)

CharacteristicCurrent smoker#Ex-smoker
IND/GLY
110/50µg
once daily
SFC
50/500µg
twice daily
IND/GLY
110/50µg
once daily
SFC
50/500µg
twice daily
Subjects n87989014271421
Age years62.1±7.5162.0±7.0766.0±7.8066.0±7.76
Male643 (73.2)638 (71.7)1175 (82.3)1136 (79.9)
BMI kg·m−225.0±5.0025.1±5.2426.0±5.0726.1±4.95
Estimated number of pack-years43.0±18.5144.4±21.8839.6±22.5839.3±22.00
Duration of COPD years6.0±4.756.3±5.137.2±5.547.4±5.60
Blood eosinophil count at baseline cells·µL−1205.4±141.32205.9±160.36209.5±156.47207.1±166.62
Severity of airflow limitation, GOLD 2019 [25]
 Mild, GOLD 12 (0.2)1 (0.1)
 Moderate, GOLD 2386 (43.8)397 (44.6)573 (40.2)573 (40.3)
 Severe, GOLD 3437 (49.6)442 (49.6)761 (53.3)758 (53.3)
 Very severe, GOLD 447 (5.3)44 (4.9)85 (6.0)80 (5.6)
 Missing9 (1.0)7 (0.8)8 (0.6)11 (0.8)
Treatments at baseline+
 LABA430 (48.8)453 (50.8)698 (48.9)674 (47.5)
 LAMA393 (44.6)415 (46.6)613 (43.0)612 (43.0)
 ICS442 (50.2)448 (50.3)826 (57.9)802 (56.4)
 LABA/ICS283 (32.1)295 (33.1)501 (35.1)483 (34.0)
COPD exacerbation history
 0209 (23.7)200 (22.4)361 (25.3)340 (23.9)
 1549 (62.3)570 (64.0)863 (60.5)878 (61.7)
 ≥2123 (14.0)120 (13.5)203 (14.2)204 (14.3)

Data are presented as mean±sd or n (%), unless otherwise stated. IND/GLY: indacaterol/glycopyrronium; SFC: salmeterol/fluticasone; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid. #: N=1769; : N=2848; +: patients might be on more than one COPD therapy at baseline.